glp-1 trial alcohol obesity

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial — Phot

5 Proven Ways Obesity Treatment Cuts Heavy Drinking

Obesity treatment with semaglutide can cut heavy drinking days by about 40 percent while also promoting meaningful weight loss. In a double-blinded trial of 138 participants, semaglutide reduced heavy drinking days by 41% compared with placebo, offering a clear statistical signal that a single GLP-1 drug can tackle two public-health